

**Uterine natural killer cells mediate dedifferentiation of spiral artery vascular smooth muscle cells in early human pregnancy**

A. Robson<sup>1</sup>, G.E. Lash<sup>2</sup>, B.A. Innes, J.Y. Zhang<sup>2</sup>, S.C. Robson, J.N. Bulmer\*

Reproductive and Vascular Biology Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; <sup>1</sup>Current address; Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK; <sup>2</sup>Current address; Guangzhou Women and Children's Medical Center, Guangzhou, China

**Running title:** Uterine spiral artery muscle dedifferentiation

**\*Correspondence address:** Dr Judith N Bulmer, Reproductive and Vascular Biology Group, Institute of Cellular Medicine, 3<sup>rd</sup> Floor William Leech Building, Newcastle upon Tyne, NE2 4HH, UK

Telephone +44 191 208 5213

Fax +44 191 208 5066

e-mail: [judith.bulmer@ncl.ac.uk](mailto:judith.bulmer@ncl.ac.uk)

## Abstract

**Study question:** Is vascular smooth muscle cell (VSMC) dedifferentiation a feature of uterine spiral artery (SpA) remodelling in early human pregnancy?

**Summary answer:** Remodelling of human uterine SpAs is associated with dedifferentiation of VSMCs and can be induced in vitro by uterine natural killer (uNK) cells and extravillous trophoblast cells (EVTs).

**What is known already:** Uterine SpAs undergo profound morphological changes in normal pregnancy with replacement of the musculoelastic arterial wall structure by fibrinoid containing EVTs. The fate of VSMCs in SpA remodelling is unknown; in guinea pig uterine artery VSMCs dedifferentiate, remain in the vessel wall and differentiate after parturition to restore the arterial wall. There is increasing evidence that uNK cells play a role in SpA remodelling. We hypothesised that SpA remodelling in human pregnancy is associated with VSMC dedifferentiation, initiated by uNK cell derived growth factors.

**Study design, size, duration:** Formalin fixed, paraffin embedded placental bed biopsies were immunostained for angiogenic growth factor (AGF) receptors and markers of VSMC differentiation. An in vitro model of SpA remodelling using chorionic plate arteries (CPAs) was used to test the effect of different cell types and AGFs on VSMC differentiation.

**Participants/materials, setting, methods:** Placental bed biopsies were immunostained for vascular endothelial growth factor receptors 1-3 (VEGF-R1, VEGF-R2, VEGF-R3), transforming growth factor beta 1 receptors I and II (TGF- $\beta$ RI, TGF- $\beta$ RII), interferon gamma receptors 1 and 2 (IFN- $\gamma$ R1, IFN- $\gamma$ R2), Tie2,  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), H-caldesmon (H-Cal), myosin heavy chain (MyHC), osteopontin and smoothelin. Staining intensity was assessed using a modified quickscore. Expression

by VSMCs of the AGF receptors was confirmed by laser capture microdissection and real time RT-PCR of non-remodelled SpAs, after laser removal of the endothelium. As an in vitro model, VSMC differentiation was assessed in CPAs by immunohistochemistry after culture in uNK cell conditioned medium (CM), EVT-CM, uNK cell/EVT co-culture CM, Ang-1, Ang-2, IFN- $\gamma$ , VEGF-A and VEGF-C, and after blocking of both Ang-1 and Ang-2 in uNK-CM.

**Main results and the role of chance:** SpA VSMC expression of Tie-2 ( $P=0.0007$ ), VEGF-R2 ( $P=0.005$ ) and osteopontin ( $P=0.0001$ ) increased in partially remodelled SpAs compared with non-remodelled SpAs, while expression of contractile VSMC markers was reduced ( $\alpha$ -SMA  $P<0.0001$ , H-Cal  $P=0.03$ , MyHC  $P=0.03$ , smoothelin  $P=0.0001$ ). In the in vitro CPA model, supernatants from purified uNK cell (H-Cal  $P<0.0001$ , MyHC  $P=0.03$ ,  $\alpha$ -SMA  $P=0.02$ , osteopontin  $P=0.03$ ), EVT (H-Cal  $P=0.0006$ , MyHC  $P=0.02$ , osteopontin  $P=0.01$ ) and uNK cell/EVT co-cultures (H-Cal  $P=0.001$ , MyHC  $P=0.05$ , osteopontin  $P=0.02$ ) at 12-14 weeks, but not 8-10 weeks, gestational age induced reduced expression of contractile VSMC markers, and increased osteopontin expression. Addition of exogenous (10ng/ml) Ang-1 ( $P=0.006$ ) or Ang-2 ( $P=0.009$ ) also reduced H-Cal expression in the CPA model. Inhibition of Ang-1 ( $P=0.0004$ ) or Ang-2 ( $P=0.004$ ) in uNK cell supernatants blocked the ability of uNK cell supernatants to reduce H-Cal expression.

**Limitations, reasons for caution:** This is an in vitro study and the role of uNK cells, Ang-1 and Ang-2 in SpA remodelling in vivo has not yet been shown.

**Wider implications of the findings:** VSMC dedifferentiation is a feature of early SpA remodelling and uNK cells and EVT play key roles in this process by secretion of Ang-1 and Ang-2. This is one of the first studies to suggest a direct role for Ang-1 and Ang-2 in VSMC biology.

**Study funding/competing interest(s):** This work was supported by a grant from British Biotechnology and Biosciences Research Council (BB/E016790/1). The authors have no competing interests to declare.

75

**Key Words:** vascular smooth muscle cells; dedifferentiation; spiral arteries; uterine natural killer cells; vascular remodelling; [human pregnancy](#)

**Commented [CF1]:** You can have up to 5 more keywords if you wish.

80 **Introduction**

Uterine spiral arteries (SpA) in decidualised endometrium and inner myometrium undergo profound morphological changes in successful human pregnancy. Deficient SpA remodelling occurs in various pregnancy complications, including pre-eclampsia, fetal growth restriction, preterm labour and late miscarriage (Brosens et al., 2011). As  
85 well as direct fetal and maternal morbidity and mortality, these conditions may also impact on health in later life for mothers and surviving babies (Barker, 2007; Brown et al., 2013; Wu et al., 2017).

SpA remodelling is characterised by replacement of medial vascular smooth muscle  
90 cells (VSMCs), extracellular matrix and elastic lamina by amorphous fibrinoid material containing intramural extravillous trophoblast cells (EVTs) (Pijnenborg et al., 2006; Smith et al., 2016). EVT invasion is required for complete SpA remodelling but there is increasing evidence for a maternal-mediated 'priming' phase preceding EVT invasion: 'decidua-associated' or 'trophoblast-independent' remodelling (Pijnenborg et al.,  
95 2006). SpAs in early pregnancy show dilatation, endothelial cell vacuolisation and basophilia, and VSMC hyperplasia, vacuolisation, separation and disorganisation in the absence of EVTs (Craven et al., 1998; Kam et al., 1999; Pijnenborg et al., 2006).

CD56+ uterine natural killer (uNK) cells account for up to 70% of leucocytes in decidual  
100 stroma in the first trimester (Bulmer et al., 1991); their accumulation around SpAs suggests a role in remodelling (Smith et al., 2009; Lash et al., 2016). Furthermore, uNK cells from early pregnancy decidua produce a range of angiogenic growth factors (AGFs) including angiopoietin-1 (Ang-1), Ang-2, transforming growth factor beta 1 (TGF- $\beta$ 1), vascular endothelial growth factor-C (VEGF-C), interleukin 8 (IL-8) and

105 interferon gamma (IFN- $\gamma$ ) (Hanna et al., 2006; Lash et al., 2006), all of which can cause morphological changes to pre-existing vascular networks (Distler et al., 2003; Ferrara, 2004). Using an *in vitro* model of SpA remodelling we have demonstrated that uNK cells from early human pregnancy can induce morphological changes in VSMCs (Robson et al., 2012).

110 The cellular mechanisms that underlie medial VSMC loss in SpAs in human pregnancy are not fully understood. Apoptosis has been suggested (Smith et al., 2009), but appears to be a rare event within the SpA artery wall itself (Bulmer et al., 2012). However, VSMCs migrate away from the SpA wall into decidual stroma during remodelling where they then appear to undergo apoptosis (Bulmer et al., 2012; Lash  
115 et al., 2016). In guinea pig, uterine VSMCs exhibit polygonal morphology and loss of desmin and  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) in pregnancy, with restoration three days post-parturition, suggesting that uterine VSMCs dedifferentiate during artery remodelling (Nanaev et al., 1995, 2000).

120 VSMCs can switch from contractile to synthetic phenotype according to local environmental cues (McDonald and Owens, 2007). Contractile VSMCs are elongated, spindle shaped cells characterised by high expression of contractile marker proteins such as  $\alpha$ -SMA, H-caldesmon (H-cal) and myosin heavy chain (MyHC), whereas  
125 synthetic VSMCs have low contractile marker expression, less elongated rhomboid morphology and are more motile (Rensen et al., 2007). Modifiers of VSMC phenotype *in vitro* include biochemical factors such as platelet derived growth factor (PDGF) and TGF- $\beta$ 1, extracellular matrix components and physical factors such as tensile stress (Rensen et al., 2007; Rzuclido et al., 2007).

130

In view of reports of uterine artery VSMC dedifferentiation in guinea pig, VSMC motility in humans and high AGF secretion by uNK cells, we hypothesised that VSMCs undergo dedifferentiation during SpA remodelling, mediated by paracrine signalling through uNK cell derived factors. To test this hypothesis, we examined expression of

135 VSMC differentiation markers in both non-remodelled SpAs and SpAs in early stages of remodelling in the absence of EVT and used an *in vitro* model to determine which uNK cell derived AGFs may initiate VSMC dedifferentiation.

## Materials and Methods

### Samples

Placental bed biopsies for immunohistochemical studies were obtained as previously described (Robson et al., 2002) after elective surgical termination of apparently normal pregnancy at 8-14 weeks gestational age (n=15). Placenta and decidua for uNK cell and EVT cultures were obtained at 8-10 and 12-14 weeks gestational age from women undergoing elective pregnancy termination (n=10 each group). Chorionic plate artery (CPA) segments were obtained from normal term placenta delivered by elective caesarean section (n=13). The study had local ethical approval (National Research Ethics Service Committee Sunderland, ref 07/H0904/74; Newcastle & North Tyneside 1, ref 10/H0906/71) and written informed consent was obtained from all subjects.

Formalin fixed, paraffin embedded placental bed biopsies were sectioned at 3µm and immunostained as described previously to confirm the presence of decidua, myometrium, EVT and SpAs (Robson et al., 2002). Samples selected contained non-remodelled SpAs or SpAs with features of early partial remodelling (dilatation, VSMC separation and morphological change) (Lash et al., 2016).

### Immunohistochemistry

Immunohistochemistry was performed on paraffin sections as described previously (Schiessl et al., 2009) using an avidin-biotin peroxidase method (Vectastain Elite, Vector Laboratories, Peterborough, UK). Primary antibody specificities, dilutions, pre-treatments and incubation conditions are shown in Table I. Sections were lightly counterstained with Mayer's haematoxylin (BDH, Poole, UK) and mounted with DPX



synthetic resin (Raymond Lamb, London, UK). Appropriate positive controls were performed in each staining run and a negative control was performed for each sample by replacing the antibody with non-immune serum. For any individual antibody, all the samples to be analysed were stained in a single staining run with the appropriate positive control to avoid day to day variation.

#### **Laser capture microdissection and real time RT-PCR**

Laser capture microdissection and RT-PCR was used to confirm the presence or absence of mRNA corresponding to AGF receptor expression in VSMCs identified by immunohistochemistry.

10µm cryosections of placental bed biopsies (n=6) were cut onto 2µm PEN-Membrane slides (Leica Microsystems, Wetzlar, Germany) and stained with cresyl violet LCM staining kit (Ambion, TX, USA) to allow SpA identification. Initially the lumen and endothelial cells were laser microdissected using a Leica AS LMD microscope (Leica Microsystems) and removed as waste. The remaining SpA wall containing VSMCs was then laser microdissected and used for RT-PCR.

Total RNA was extracted using RNAqueous Micro (Ambion) and reverse transcribed to cDNA using Superscript III (Invitrogen, Paisley, UK). Real time RT-PCR was performed using Taqman chemistry, 2µl cDNA per 20µl reaction with Taqman Universal PCR MasterMix (Applied Biosystems, CA, USA) and run on an ABI7000 real time PCR machine (Applied Biosystems). Probe/primer sets were purchased from Assays on Demand (Applied Biosystems) for GAPDH (housekeeping gene), Tie-2, TGF-βRI, TGF-βRII, VEGF-R1, VEGF-R2, VEGF-R3, IFN-γR1 and IFN-γR2. Due to

the very small size of the laser capture dissected samples and the number of genes  
190 investigated the concentration of cDNA was extremely limited. PCR reactions were  
therefore run for 50 cycles. All probe/primer sets were validated for use with a  
laboratory standard total RNA extracted from early pregnancy decidua.

#### **Isolation and culture of CD56<sup>+</sup> uNK cells, EVT and uNK cell/EVT co-cultures**

195 Decidua and placenta were taken from the same patient for isolation of both uNK cells  
and EVTs.

uNK cell-enriched isolates were prepared by enzymatic disaggregation and positive  
immunomagnetic selection (Miltenyi Biotech, Bisley, UK) as described previously  
200 (Lash et al., 2006). To prepare uNK cell-conditioned medium (uNK-CM), cells were  
cultured at  $1 \times 10^6$  cells/ml in RPMI1640 complete medium (RPMI containing 10% (v/v)  
fetal calf serum, ~~1%~~5U/ml penicillin, ~~0.05mg/ml~~ streptomycin, ~~1%~~1.5µg/ml  
amphotericin; Sigma-Aldrich). After 24 hours the uNK-CM was removed, centrifuged  
and stored at -80 °C. Cell purity and viability were tested routinely by immunostaining  
205 cell smears and trypan blue exclusion, respectively; both were consistently >95%.

EVTs were isolated as previously described (Lash et al., 2010a) and cultured at  $1 \times 10^6$   
cells/ml in DMEM:Ham's F12 (Sigma-Aldrich) complete medium in a 24 well plate  
coated with growth factor reduced Matrigel (BD Biosciences, Oxford, UK).  
210 Conditioned medium was harvested (EVT-CM) after 24 hours, centrifuged and stored  
at -80 °C. Cell purity and viability were assessed after 24 hours of culture by  
immunostaining cell smears (HLA-G, cytokeratin 7) (Lash et al., 2010a) and trypan  
blue exclusion, respectively; both were consistently >95%.

**Commented [CF2]:** When concentrations are specified by percent please always say whether this was calculated v/v, w/v or whatever is correct.  
I HAVE CHANGED TO GIVE THE CONCENTRATION - APOLOGIES

215 For co-culture of uNK cells and EVT<sub>s</sub>, 1x10<sup>6</sup> EVT cells were cultured in DMEM:F12  
complete medium in a 24 well plate overnight prior to addition of 1x10<sup>6</sup> uNK cells (from  
the same patient) in DMEM:Ham's F12 to a total volume of 1ml (Lash et al., 2011;  
Robson et al., 2012). After 24 hours co-culture, the conditioned medium (uNK/EVT-  
CM) was removed, centrifuged and stored at -80 °C. Viability of co-cultures was  
220 assessed after 24 hours of culture and was consistently >95%.

#### Isolation and culture of chorionic plate arteries

Intact CPA segments (5mm length) (Robson et al., 2012; Pitman et al., 2013; Lash et  
al., 2016) were dissected from normal term placenta and cultured at 37 °C in 5% CO<sub>2</sub>  
225 in: (A) conditioned medium: 20% (v/v) uNK-CM, EVT-CM or uNK/EVT-CM (8-10 or 12-  
14 weeks' gestation; n=6 each gestational age group and CM type); (B) angiogenic  
growth factors: 1ng/ml and 10ng/ml VEGF-A, VEGF-C, Ang-1, Ang-2, IFN-γ or TGF-  
β1 (all from R&D Systems, Abingdon, UK; n=10 each growth factor); (C) conditioned  
medium and anti-angiogenic growth factor neutralising antibody: 20% (v/v) uNK-CM,  
230 EVT-CM or uNK/EVT-CM (8-10 or 12-14 weeks gestation; n=5 each experiment) with  
or without anti-Ang-1 (1μg/ml; Millipore, Watford, UK), anti-Ang-2 (10μg/ml; Amgen,  
Seattle, Washington); or (D) medium only controls: RPMI1640 complete medium  
control and a citric acid control for TGF-β1, which is reconstituted in citric acid. The  
medium was replaced every 48 hours. CPAs were harvested after 120 hours, fixed in  
235 formalin for 24 hours and embedded in paraffin wax. Three μm serial sections were  
immunostained for: H-cal, MyHC and α-SMA to determine the differentiation state of  
CPA VSMCs after culture; cleaved caspase-3 to verify cell viability; Ki67 to examine

**Commented [CF3]:** Journal style forbids starting a sentence  
with a numeral.  
APOLOGIES

cell proliferation in order to ensure that any differences detected were not due to altered cell proliferation; and CD31 to confirm endothelial integrity.

240

### **Analysis of immunostaining**

For assessment of VSMC differentiation marker expression, digital images of immunostained decidual SpAs and CPAs were captured using a Nikon Eclipse 80i microscope coupled with a DS-Fi1 camera and NIS elements D software. In Adobe Photoshop (Adobe Systems Inc., San Jose, CA, USA) individual SpAs were selected using the magnetic lasso tool and copied to a new layer within the image, where a positively stained area was identified by eye and selected using the magic wand tool. Other immunopositive areas were then selected using the 'similar' command, with the threshold level set such that all positive areas but no negative areas were selected. The immunopositive areas were then copied into a new layer. The pixel number in each layer was noted and the number of positive pixels in immunostained sections was expressed as a percentage of the total pixel number in the vessel wall for each SpA or CPA segment (Pitman et al., 2013; Lash et al., 2016).

255 VSMC immunostaining for AGF receptors was assessed in non-remodelled (n=33 SpAs) and partially remodelled (n=33 SpAs) SpAs using a modified quickscore taking into account both percentage of cells stained and intensity of staining (Schiessl et al., 2009). The degree of remodelling was determined in serial sections immunostained for MyHC and cytokeratin 7 with non-remodelled SpA showing no signs of remodelling and partially remodelled SpA displaying separated and rounded VSMCs but no associated EVT.

### Statistical Analysis

265 Data are presented as mean  $\pm$  standard error of the mean (SEM). Statistical analyses were performed using the StatView statistical software package (Abacus Concepts, Berkley, CA, USA). Statistical significance was determined using a one-way ANOVA, followed by Fisher's post hoc analysis unless otherwise stated. Differences were considered statistically significant at  $P < 0.05$ .

## Results

### ***Uterine spiral arteries express receptors for angiogenic growth factors***

We investigated AGF receptor expression by VSMCs in non- and partially remodelled SpAs (Figure 1A). There was moderate to strong expression of VEGF-R1 and VEGF-R2 in SpA VSMCs, with weaker VEGF-R3 expression. TGF- $\beta$ RI, TGF- $\beta$ RII and IFN- $\gamma$ R1 were moderately expressed, although IFN- $\gamma$ R2 immunoreactivity was weaker. Tie-2, the receptor for Ang-1 and Ang-2 was weakly to moderately expressed. Scores for most AGF receptors did not differ between non- and partially remodelled SpAs (Figure 1B) but immunostaining was increased in partially remodelled compared with non-remodelled SpAs for VEGF-R2 ( $P=0.005$ ) and Tie-2 ( $P=0.0007$ ) (Figure 1A, 1B).

Expression of mRNA for VEGF-R1, VEGF-R2, VEGF-R3, TGF- $\beta$ RI, TGF- $\beta$ RII, IFN- $\gamma$ R1, IFN- $\gamma$ R2 and Tie-2 in VSMCs of SpAs was confirmed with laser capture microdissection coupled with real-time RT-PCR in all samples examined ( $n=6$  samples; Figure 1C). PCR reactions were run for 50 cycles and for each gene the cycle number at threshold was higher than ideal. However, all reactions demonstrated classical amplification curves and reached saturation prior to 50 cycles (GAPDH 31, H-cal 35, Tie-2 34, IFN $\gamma$ -R1 40, IFN $\gamma$ -R2 34, TGF- $\beta$ RI 34, TGF- $\beta$ RII 31, VEGF-R1 26, VEGF-R2 38, VEGF-R3 37).

### ***Vascular smooth muscle cells of partially transformed spiral arteries switch from a contractile to a more synthetic phenotype***

Markers of contractile ( $\alpha$ -SMA, calponin, H-cal, MyHC, smoothelin) and synthetic (osteopontin) VSMC phenotype were compared between non- and partially remodelled SpAs ( $n=15$  SpAs each group) at 8-14 weeks gestational age (Figure 2A).

Partially remodelled SpAs showed endothelial swelling and separation of medial  
295 VSMCs but no intramural or endovascular EVTs, [indicating an early stage of SpA  
remodelling prior to invasion of vessel wall and lumen by EVTs](#) (7); SpAs were  
classified as non- and partially remodelled by two investigators (JNB, AR).

Commented [CF4]: Please explain the significance of this.

Expression of H-cal ( $P=0.0003$ ),  $\alpha$ -SMA ( $P<0.0001$ ), MyHC ( $P=0.001$ ), and smoothelin  
300 ( $P=0.0001$ ) was reduced and osteopontin ( $P=0.008$ ) expression was increased in  
partially compared with non-remodelled SpAs. In order to correct for the possibility  
that the number of VSMCs in SpAs was reduced in partially remodelled SpA,  
immunopositivity for each VSMC marker was also expressed as a percentage of  
calponin immunopositivity (Figure 2B), an early marker of VSMC differentiation whose  
305 expression remained high and showed minimal changes in expression in partially  
remodelled vessels. When expressed as a percentage of calponin immunoreactivity,  
expression of  $\alpha$ -SMA ( $P<0.0001$ ), H-cal ( $P=0.03$ ), MyHC ( $P=0.03$ ) and smoothelin  
( $P=0.0001$ ) was reduced and osteopontin ( $P=0.0001$ ) was increased in partially  
remodelled SpAs compared with non-remodelled SpAs (Figure 2A, 2B). These results  
310 suggest that in the early stages of remodelling SpA VSMCs show loss of their  
contractile phenotype, adopting a more synthetic or dedifferentiated phenotype.

#### ***uNK cell, EVT and uNK cell:EVT conditioned medium stimulates VSMC dedifferentiation in chorionic plate arteries in vitro***

315 We tested the hypothesis that uNK cells initiate VSMC dedifferentiation by  
quantification of  $\alpha$ -SMA, H-cal, MyHC and osteopontin immunoreactivity in an *in vitro*  
CPA model (Robson et al., 2012; Pitman et al., 2013; Lash et al., 2016). Expression

by CPA VSMC of receptors for Ang-1, Ang-2, IFN- $\gamma$ , TGF- $\beta$ 1, VEGF-A and VEGF-C was initially confirmed by immunohistochemistry (Figure 3C).

**Commented [CF5]:** Figures must be numbered in the order in which they are cited so the numbering of Figure 3 and 4 needs to be reversed  
THANKS

All CPAs were immunostained for caspase 3, Ki67 and CD31 after culture. There was no evidence of caspase 3 immunopositivity, confirming viability. The endothelium was intact as demonstrated by immunostaining for CD31; CD31-negative vessels (reflecting endothelial loss) were excluded from the study. There was minimal Ki67 immunopositivity, confirming that proliferation was not altered after culture. CPAs cultured with uNK-CM, EVT-CM or uNK/EVT-CM from 8-10 weeks gestational age showed no difference in H-cal, MyHC,  $\alpha$ -SMA or osteopontin expression (Figure 4A-4D) compared with medium only controls. However, reduced H-cal and MyHC expression was observed after culture in uNK-CM (H-cal  $P<0.0001$ ; MyHC  $P=0.03$ ), EVT-CM (H-cal  $P=0.0006$ ; MyHC  $P=0.02$ ) or uNK/EVT-CM (H-cal  $P=0.001$ ; MyHC  $P=0.05$ ) from 12-14 weeks gestational age (Figure 4A, 4B). Osteopontin expression was increased after culture in uNK-CM ( $P=0.03$ ), EVT-CM ( $P=0.01$ ) and uNK/EVT-CM ( $P=0.02$ ) from 12-14 weeks gestational age (Figure 4D).  $\alpha$ -SMA expression was reduced only after culture in uNK-CM ( $P=0.02$ ) from 12-14 weeks gestational age samples (Figure 4C).

#### ***Ang-1 and Ang-2 reduce H-cal expression in CPA***

To identify whether AGFs produced by uNK cells mediate VSMC dedifferentiation, CPAs were cultured with 1ng/ml and 10ng/ml recombinant AGFs and H-cal expression assessed. There was no effect on H-cal expression after incubation of CPAs with both concentrations of IFN- $\gamma$ , VEGF-A and VEGF-C (Figure 3A). 1ng/ml Ang-1 and Ang-2 also had no effect but incubation of CPAs in 10ng/ml recombinant human Ang-1



( $P=0.006$ ) and Ang-2 ( $P=0.009$ ) reduced VSMC expression of H-cal (Figure 3A). TGF- $\beta$ 1 was excluded from this part of the study since the citric acid used to reconstitute  
345 TGF- $\beta$ 1 reduced expression of the VSMC marker studied (data not shown).

***Neutralisation of uNK cell secreted Ang-1 and Ang-2 activity partially restored contractile VSMC marker expression***

Neutralising antibodies to Ang-1 or Ang-2 were added to 12-14 week gestational age  
350 uNK-CM and CPAs cultured for 120 hours. Neutralisation of both Ang-1 ( $P=0.0004$ ) and Ang-2 ( $P=0.004$ ) restored H-cal expression (Figure 3B).

## Discussion

In the current study we have demonstrated that in early remodelling, in the absence of EVT infiltration, SpA VSMCs show loss of contractile phenotype. Furthermore, AGFs produced by uNK cells and EVTs can mediate this VSMC de-differentiation in an *in vitro* model (Lash et al., 2006, 2010a).

We have demonstrated expression of protein and mRNA for receptors for Ang-1, Ang-2, IFN- $\gamma$ , TGF- $\beta$ 1, VEGF-A and VEGF-C in uterine SpA VSMCs. Expression of VEGF-R2 and Tie-2 correlate with the high levels of VEGF-C, Ang-1 and Ang-2 secreted by uNK cells in early pregnancy and suggest a role in trophoblast-independent SpA remodelling. Interestingly, VEGF-R2 and Tie-2 expression was increased in partially remodelled SpAs, at a gestational age when levels of uNK cell secreted AGFs are decreasing (Lash et al., 2006). In partially remodelled SpAs there is separation and some dedifferentiation of VSMCs, but they are not yet lost. Increased receptor expression may reflect altered VSMC phenotype as they prepare to migrate away from the SpA. Despite high VEGF-R1 expression in SpA VSMCs, uNK secretion of VEGF-A is low, although EVTs secrete high levels of this AGF (Lash et al., 2010a). Taken together, these data confirm that SpAs express AGF receptors and are a potential target for uNK cell derived factors.

The main function of VSMCs is to control vessel contraction, thereby regulating blood vessel tone and blood pressure. VSMCs exhibit plasticity and can dedifferentiate in response to local environmental signals during vascular development or vascular injury (Owens, 1995, 2007). VSMCs acquire specific markers as they differentiate to a contractile phenotype, which are lost when they dedifferentiate into a more synthetic

phenotype. Regulation of VSMC differentiation/dedifferentiation is complex and involves local cues including mechanical forces, extracellular matrix interactions, local cytokines, growth factors and epigenetic control (Owens et al., 2004; Alexander and Owens, 2012).  $\alpha$ -SMA is the first contractile marker expressed during development, at approximately embryonic day 2.5 in chick (Owens, 1995), and is the most abundant actin isoform in mature differentiated VSMCs (Fatigati and Murphy, 1984). H-cal is the most abundantly expressed caldesmon isoform in differentiated VSMC and is a later marker of VSMC differentiation than  $\alpha$ -SMA (Sobue and Sellers, 1991; Stouffer and Owens, 1994), being expressed at around embryonic day 6 in chick (Owens, 1995). MyHC is part of the contractile apparatus in all muscle cells and consists of two isoforms SM-1 and SM-2 produced by alternative splicing. These isoforms are late markers of VSMC differentiation, with SM-2 expressed ~10 days postpartum (Fatigati and Murphy, 1984; Kuro-o et al., 1989). Calponin is a regulator of VSMC contraction and is a relatively early marker of VSMC differentiation expressed from day 4 in chick embryo (Owens, 1995). Smoothelin is a late VSMC differentiation marker and mouse knockout studies suggest that it is required for contractile potential (van Eys et al., 2007). Osteopontin is a secreted acidic glycosylated phosphoprotein that interacts with integrins and extracellular matrix; expression is increased in dedifferentiated VSMCs and osteopontin regulates expression of  $\alpha$ -SMA and calponin (Gao et al., 2012).

We demonstrated reduced immunostaining for  $\alpha$ -SMA, H-cal, MyHC and smoothelin within the walls of SpAs undergoing early remodelling prior to EVT infiltration. These data suggest that in early remodelling SpA VSMCs become less contractile; this reduced expression of contractile proteins is similar to that reported in vascular

diseases such as atherosclerosis (Ross, 1993) and may account for the dilatation in early SpA remodelling (Craven et al., 1998; Pijnenborg et al., 2006). Osteopontin expression, indicating synthetic VSMC phenotype (Weissgerber et al., 2010), was increased in the same SpAs. The functional importance of this increased osteopontin expression is unknown but osteopontin promotes VSMC migration *in vitro* (Li et al., 2007). We have demonstrated that VSMCs migrate away from the SpA wall during early SpA transformation (Bulmer et al., 2012); this may reflect a synthetic phenotype capable of migration. This is the first demonstration of phenotypic changes in SpA VSMCs in early SpA remodelling in the absence of EVT and supports evidence from guinea pig pregnancy of dedifferentiation of uterine artery VSMCs (Nanaev et al., 1995). A recent study has reported that predecidual stromal cells express pericyte markers, including  $\alpha$ -SMA and the contribution of these cells to decidual SpA remodelling should also be considered (Munoz-Fernandez et al., 2018).

Using a CPA model we assessed the effects of uNK cell, EVT and uNK cell/EVT conditioned medium on VSMC dedifferentiation *in vitro*. Both uNK cells and EVT supernatants reduced VSMC expression of H-cal, MyHC and  $\alpha$ -SMA and increased osteopontin expression. Although MyHC is the latest VSMC differentiation marker of the three examined, H-cal showed most loss in expression. A possible explanation is that the MyHC antibody recognises both SM-1 and SM-2; these isoforms may show differential regulation, although this cannot be concluded from our data. In a study using an aorta VSMC cell line,  $\alpha$ -SMA and calponin expression were decreased after culture in EVT-CM (Wallace et al., 2013). The authors hypothesised that this may be attributed to CXCL10, although this chemokine stimulated VSMC motility but had no effect on VSMC contractile protein expression (Wallace et al., 2013).

Interestingly we only observed contractile muscle protein loss after culture with  
430 supernatants from 12-14 weeks' but not 8-10 weeks' gestation. Both groups secrete  
high levels of AGFs, although levels of Ang-2 and VEGF-C were reduced at 12-14  
weeks' compared with 8-10 weeks' gestation (Lash et al., 2006). A possible  
explanation is that the SpA VSMCs must first undergo separation of the previously  
intact layers; this process is initiated by 8-10 weeks' gestation uNK cell culture  
435 supernatants (Robson et al., 2012). We also observed that EVT-CM and uNK  
cell/EVT-CM reduced expression of H-cal and MyHC, but not  $\alpha$ -SMA, although for H-  
cal the effect of EVT-CM and uNK cell/EVT-CM was not as potent as that of uNK-CM.  
These data suggest that close proximity of uNK cells and EVT cells may lead to mutual  
suppression of function; previous data from our laboratory demonstrated reduced  
440 secretion of several cytokines and AGFs in uNK cell/EVT co-cultures compared with  
cultures of individual cell types (Lash et al., 2011). The gestational age differences in  
the effect of the uNK cell and EVT supernatants suggests that this is not a non-specific  
effect. Furthermore, isolated decidual macrophages did not affect VSMC  
dedifferentiation in the CPA model, despite their production of high levels of AGFs  
445 (Lash et al., 2016).

Ang-1 and Ang-2 reduced expression of H-cal in the CPA model and addition of Ang-  
1 and Ang-2 neutralising antibody abrogated the effect of uNK-CM on H-cal expression.  
This is one of the first descriptions of Ang-1 and Ang-2 playing similar roles and having  
450 biological effects on VSMCs. The mechanism of action warrants further study.

We propose a working model of the cells and molecular mediators involved in SpA remodelling. In early gestation SpAs are surrounded by uNK cells and macrophages which facilitate breakdown of extracellular matrix in the vessel wall via matrix metalloproteinase secretion (Hazan et al., 2010; Robson et al., 2012; Lash et al., 2016).  
455 Matrix metalloproteinases have also been localised within the SpA wall itself (Hazan et al 2010). uNK cells may then induce VSMC rounding up and separation via AGFs including Ang-2 (Robson et al., 2012; Pitman et al., 2013). uNK cells also attract EVTs towards the SpAs via secretion of IL-8, CXCL10 and other cytokines (Hanna et al.,  
460 2006; Lash et al., 2010b). EVT and uNK cells interact via EVT expression of HLA-C, potentially influencing their function (Xiong et al., 2013). Both uNK cells and EVT may then induce dedifferentiation of VSMCs, through AGF secretion, particularly Ang-1 and Ang-2. This synthetic phenotype increases their motility and VSMC migrate into the stroma surrounding remodelling SpAs where they undergo apoptosis and are  
465 phagocytosed by resident macrophages (Bulmer et al., 2012; Lash et al., 2016). Disruptions in any of these cell types and molecular mediators may contribute to failed SpA remodelling and hence to the pathogenesis of pregnancy complications.

## Acknowledgements

Commented [CF6]: Always the first post text item

470 The authors thank Amgen for the Ang-2 neutralising antibody and staff on the delivery  
suite at the Royal Victoria Infirmary for help consenting and collecting samples. The  
authors also thank all those women who donated samples for these studies.

## Author Roles

475 AR performed experiments, analysed data and wrote the manuscript; GEL conceived  
the study, performed experiments and edited the manuscript; BAI performed  
experiments; SCR collected samples; JNB conceived the study and edited the  
manuscript.

## Funding

480 This work was supported by a grant from British Biotechnology and Biosciences  
Research Council (BB/E016790/1).

## Conflict of interest

485 None

Commented [CF7]: This statement has to appear here even if negative.

## References

Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. *Ann Rev Physiol* 2012;

490 **74**: 13-40.

Arnoldi R, Hiltbrunner A, Dugina V, Tille JC, Chaponnier C. Smooth muscle actin isoforms: a tug of war between contraction and compliance. *Eur J Cell Biol* 2013; **92**: 187-200.

Ball E, Bulmer JN, Ayis S, Lyall F, Robson SC. Late sporadic miscarriage is associated with abnormalities in spiral artery transformation and trophoblast invasion. *J Pathol* 2006; **208**: 535-542.

Barker DJ. The origins of the developmental origins theory. *J Intern Med* 2007; **261**: 412-417.

Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. *Am J Obstet Gynecol* 2011;**204**:193–201.

Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. *Eur J Epidemiol* 2013;**28**:1-19.

505 Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D. Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. *Hum Reprod* 1991; **6**: 791-798.

Bulmer JN, Innes BA, Levey J, Robson SC, Lash GE. The role of vascular smooth muscle cell apoptosis and migration during uterine spiral artery remodeling in normal human pregnancy. *FASEB J* 2012; **26**: 2975-2985.

510



- Craven CM, Morgan T, Ward K. Decidual spiral artery remodeling begins before cellular interaction with cytotrophoblasts. *Placenta* 1998; **19**: 241-252.
- Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. *Q J Nucl Med* 2003; **47**:  
515 149-161.
- Fatigati V, Murphy RA. Actin and tropomyosin variants in smooth muscles. Dependence on tissue type. *J Biol Chem* 1984; **259**: 14383-14388.
- Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004; **25**: 581-611.
- 520 Gao H, Steffen MC, Ramos KS. Osteopontin regulates  $\alpha$ -smooth muscle actin and calponin in vascular smooth muscle cells. *Cell Biol Int* 2012; **36**: 155-161.
- Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I *et al.* Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. *Nat Med* 2006; **12**:  
525 1065-1074.
- Hazan AD, Smith SD, Jones RL, Whittle W, Lye SJ, Dunk CE. Vascular-leukocyte interactions: mechanisms of human decidual SpA remodeling in vitro. *Am J Pathol* 2010;**177**:1017–1030.
- Kam EP, Gardner L, Loke YW, King A. The role of trophoblast in the physiological  
530 change in decidual spiral arteries. *Hum Reprod* 1999; **14**: 2131-2138.
- Kuro-o M, Nagai R, Tsuchimochi H, Katoh H, Yazaki Y, Ohkubo A, Takaku F. Developmentally regulated expression of vascular smooth muscle myosin heavy chain isoforms. *J Biol Chem* 1989; **264**: 18272-18275.

- Lash GE, Schiessl B, Kirkley M, Innes BA, Cooper A, Searle RF, Robson SC, Bulmer JN. Expression of angiogenic growth factors by uterine natural killer cells during early pregnancy. *J Leukoc Biol* 2006; **80**: 572-580.
- Lash GE, Naruse K, Innes BA, Robson SC, Searle RF, Bulmer JN. Secretion of angiogenic growth factors by villous cytotrophoblast and extravillous trophoblast in early human pregnancy. *Placenta* 2010a; **31**: 545-548.
- Lash GE, Otun HA, Innes BA, Percival K, Searle RF, Robson SC, Bulmer JN. Regulation of extravillous trophoblast invasion by uterine natural killer cells is dependent on gestational age. *Hum Reprod* 2010b; **25**: 1137-1145.
- Lash GE, Naruse K, Robson A, Innes BA, Searle RF, Robson SC, Bulmer JN. Interaction between uterine natural killer cells and extravillous trophoblast cells: effect on cytokine and angiogenic growth factor production. *Hum Reprod* 2011; **26**: 2289-2295.
- Lash GE, Pitman H, Morgan HL, Innes BA, Agwu CN, Bulmer JN. Macrophages: key regulators of vascular remodeling in human pregnancy. *J Leukoc Biol* 2016; **100**: 315-325.
- Li JJ, Han M, Wen JK, Li AY. Osteopontin stimulates vascular smooth muscle cell migration by inducing FAK phosphorylation and ILK dephosphorylation. *Biochem Biophys Res Commun* 2007; **356**: 13-19.
- McDonald OG, Owens GK. Programming smooth muscle plasticity with chromatin dynamics. *Circ Res* 2007; **100**: 1428-1441.
- Muñoz-Fernández R, de la Mata C, Prados A, Perea A, Ruiz-Magaña MJ, Llorca T, Fernández-Rubio P, Blanco O, Abadía-Molina AC, Olivares EG. Human predecidual stromal cells have distinctive characteristics of pericytes: Cell contractility,

chemotactic activity, and expression of pericyte markers and angiogenic factors.

*Placenta* 2018;**61**:39-47.

560 Nanaev A, Chwalisz K, Frank HG, Kohnen G, Hegele-Hartung C, Kaufmann P.  
Physiological dilation of uteroplacental arteries in the guinea pig depends on nitric  
oxide synthase activity of extravillous trophoblast. *Cell Tissue Res* 1995; **282**: 407-  
421.

Nanaev AK, Kosanke G, Reister F, Kemp B, Frank HG, Kaufmann P. Pregnancy-  
565 induced de-differentiation of media smooth muscle cells in uteroplacental arteries of  
the guinea pig is reversible after delivery. *Placenta* 2000; **21**: 306-312.

Owens GK. Regulation of differentiation of vascular smooth muscle cells. *Physiol Rev*  
1995; **75**: 487-517.

Owens GK. Molecular control of vascular smooth muscle cell differentiation and  
570 phenotypic plasticity. *Novartis Found Symp* 2007; **283**: 174-241.

Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle  
cell differentiation in development and disease. *Physiol Rev* 2004; **84**: 767-801.

Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human  
pregnancy: facts and controversies. *Placenta* 2006; **27**: 939-958.

575 Pitman H, Innes BA, Robson SC, Bulmer JN, Lash GE. Altered expression of  
interleukin-6, interleukin-8 and their receptors in decidua of women with sporadic  
miscarriage. *Hum Reprod* 2013; **28**: 2075-2086.

Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular  
smooth muscle cell phenotypic diversity. *Neth Heart J* 2007; **15**: 100-108.

580 Robson A, Harris LK, Innes BA, Lash GE, Aljunaidy MM, Aplin JD, Baker PN, Robson SC, Bulmer JN. Uterine natural killer cells initiate spiral artery remodeling in human pregnancy. *FASEB J* 2012; **26**: 4876-4885.

Robson SC, Simpson H, Ball E, Lyall F, Bulmer JN. Punch biopsy of the human placental bed. *Am J Obstet Gynecol* 2002; **187**: 1349-1355.

585 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 1993; **362**: 801-809.

Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. *J Vasc Surg* 2007; **45**: A25-32.

Schiessl B, Innes BA, Bulmer JN, Otun HA, Chadwick TJ, Robson SC, Lash GE.

590 Localization of angiogenic growth factors and their receptors in the human placental bed throughout normal human pregnancy. *Placenta* 2009; **30**: 79-87.

Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. *Am J Pathol* 2009; **174**: 1959-1971.

595 Smith SD, Choudhury RH, Matos P, Horn JA, Lye SJ, Dunk CE, Aplin JD, Jones RL, Harris LK. Changes in vascular extracellular matrix composition during decidual spiral arteriole remodeling in early human pregnancy. *Histol Histopathol* 2016; **31**: 557-571.

Sobue K, Sellers JR. Caldesmon, a novel regulatory protein in smooth muscle and

600 nonmuscle actomyosin systems. *J Biol Chem* 1991; **266**: 12115-12118.

Stouffer GA, Owens GK. TGF-beta promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. *J Clin Invest* 1994; **93**: 2048-2055.

- van Eys GJ, Niessen PM, Rensen SS. Smoothelin in vascular smooth muscle cells.  
605 *Trends Cardiovasc Med* 2007; **17**: 26-30.
- Wallace AE, Cartwright JE, Begum R, Laing K, Thilaganathan B, Whitley GS.  
Trophoblast-induced changes in C-x-C motif chemokine 10 expression contribute to  
vascular smooth muscle cell dedifferentiation during spiral artery remodeling.  
*Arterioscler Thromb Vasc Biol* 2013; **33**: e93-e101.
- 610 Weissgerber TL, Davies GA, Roberts JM. Modification of angiogenic factors by regular  
and acute exercise during pregnancy. *J Appl Physiol* 2010; **108**: 1217-1223.
- Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, Zaman A, Fryer  
AA, Kadam U, Chew-Graham CA, Mamas MA. Preeclampsia and  
future cardiovascular health: A systematic review and meta-analysis. *Circ*  
615 *Cardiovasc Qual Outcomes* 2017;**10 pii**: e003497.
- Xiong S, Sharkey AM, Kennedy PR, Gardner L, Farrell LE, Chazara O, Bauer J, Hiby  
SE, Colucci F, Moffett A. Maternal uterine NK cell-activating receptor KIR2DS1  
enhances placentation. *J Clin Invest* 2013;**123**:4264–4272.

**Table I: Primary antibodies for immunohistochemistry**

<b>Antibody</b>	<b>Pre-Treatment</b>	<b>Dilution</b>	<b>Incubation Time</b>	<b>Species</b>	<b>Company</b>	<b>Clone/Cat#</b>
Tie-2	EDTA <sup>1</sup>	1:200	60 mins	Goat	R&D, Abingdon, UK	AF313
IFN- $\gamma$ R2	EDTA	1:100	60 mins	Mouse	Abcam, Cambridge, UK	31606
IFN- $\gamma$ R1	Nil	1:50	60 mins	Rabbit	Abcam	61179
VEGF-R1	Citrate <sup>2</sup>	1:200	60 mins	Rabbit	Insight Biotech, Wembley, UK	9029
VEGF-R2	Citrate	1:100	60 mins	Mouse	Insight Biotech	6251
VEGF-R3	Citrate	1:500	60 mins	Rabbit	Insight Biotech	321
TGF- $\beta$ RI	EDTA	1:50	60 mins	Rabbit	Abcam	31013
TGF- $\beta$ RII	Citrate	1:100	30 mins	Rabbit	Abcam	28382
H-caldesmon	Citrate	1:100	60 mins	Mouse	Dako, Ely, UK	M3557
Calponin	Trypsin <sup>3</sup>	1:80	30 mins	Mouse	Dako	M3556
Myosin Heavy Chain	Citrate	1:600	60 mins	Mouse	Sigma-Aldrich, Poole, UK	M7786
$\alpha$ -smooth muscle actin	Trypsin	1:75	30 mins	Mouse	Leica, Milton Keynes, UK	SMA
Smoothelin	Citrate	1:100	60 mins	Mouse	Abcam	8969
Cleaved-caspase 3	Citrate	1:200	30 mins	Mouse	Cell Signalling, New England Biolabs, Hitchin, UK	9661
Ki67	Citrate	1:200	30 mins	Mouse	Leica	MMI
CD31	Citrate	1:20	60 mins	Mouse	Leica	IAIO

<sup>1</sup>EDTA: pressure cook for 1 min in EDTA buffer pH 8<sup>2</sup>citrate: pressure cook for 1 min in citrate buffer pH 6<sup>3</sup>trypsin: incubate in 0.1% trypsin for 10 mins at 37°C

625 **Figure Legends**

**Figure 1:** Angiogenic growth factor receptors during spiral artery remodeling **A)** Representative photomicrographs of immunostaining for angiogenic growth receptors in non-remodelled (top 3 rows) and partially remodelled (bottom row) superficial myometrial spiral arteries in placental bed biopsies. The antibodies used are shown on the photomicrographs. Immunoreactivity for vascular endothelial growth factor receptor 2 (VEGF-R2) and Tie-2 is increased in the wall of the partially remodelled artery compared with the non-remodelled artery. Scale bar 50µM. **B)** Graphical representation of quickscore for receptor expression in non-remodelled and partially remodelled spiral arteries. **C)** Non-transformed spiral arteries were laser capture microdissected from sections of placental bed biopsies stained with cresyl violet. Real time RT-PCR was performed for GAPDH, H-caldesmon (Hcal), VEGF-R1, VEGF-R2, VEGF-R3, transforming growth factor beta receptors (TGFβ-R1, TGFβ-R2), interferon gamma receptors (IFNγ-R1, IFNγ-R2) and Tie-2. As there is no comparator, data are shown as delta Ct relative to GAPDH. Note that the lower the number the more abundant the mRNA. Data are shown as mean±SEM.

**Figure 2:** Loss of contractile phenotype during spiral artery remodelling **A)** Representative photomicrographs of immunostaining for cytokeratin 7 (demonstrating absence of trophoblast), α-SMA, H-Cal, MyHC, osteopontin and calponin and smoothelin in vascular smooth muscle cells of non-remodelled and partially remodelled spiral arteries in placental bed biopsies. Scale bar 50µM. **B)** Quantification of α-SMA, H-Cal, MyHC, osteopontin and smoothelin in vascular smooth muscle cells of non-remodelled (n=15) and partially remodelled (n=15) spiral arteries normalised to calponin expression. Statistical significance was determined by use of an unpaired t-Test.

**Commented [CF8]:** Figure legends need a brief title before the separate sections are described. Please check that my suggestions are appropriate.  
CHECKED AND FINE


**Commented [CF9]:** Please confirm that this is correct. We need to know which images refer to what stage of SpA development. Otherwise add labels like Figure 2.  
APOLOGIES – YES THIS IS CORRECT AND I HAVE ADDED (TOP 3 ROWS) FOR THE NON-REMODELLED ARTERIES

**Commented [CF10]:** Nowadays, many authors do not define abbreviations for protein names. However, you have done so elsewhere in the paper and I think it is good practice. Human Reproduction tries to make figures with their legend intelligible without reference elsewhere so logically abbreviations have to be defined even if already defined elsewhere.  
THANKS.

**Commented [JB11]:** I am not sure why this has been deleted. The cytokeratin 7 staining was added at the request of one of the reviewers.

**Commented [JB12]:** We omitted the smoothelin immunostain to add the cytokeratin 7 – apologies for the error

Figure 1



650

**Figure 3:** Vascular smooth muscle cell dedifferentiation by uterine natural killer cell derived growth factors **A)** Chorionic plate arteries (CPAs) were incubated with recombinant human growth factors (0, 1 or 10ng/ml) for 120 hours. Transverse sections of each artery were stained with H-Cal and quantified for amount of expression using Adobe Photoshop. Statistical significance was determined by use of an ANOVA with a Fisher's post-hoc test, n=8 each group. **B)** CPAs were incubated in uterine natural killer cell conditioned medium (uNK-CM) in the presence or absence of Ang-1 or Ang-2 neutralising antibodies (Ab; 1-2µg/ml) for 120 hours. Transverse sections of each artery were stained with H-Cal and quantified for amount of expression using Adobe Photoshop. Statistical significance was determined by use of an ANOVA with a Fisher's post-hoc test, n=5 each group. **C)** Immunostaining of CPAs for Tie-1 and Tie-2. Note immunopositivity of VSMCs.

**Figure 4:** Dedifferentiation of chorionic plate arteries (CPAs). CPAs were incubated with unconditioned medium (control; 20% (v/v)), uterine natural killer cell conditioned medium (uNK-CM), extravillous trophoblast (EVT)-CM or uNK/EVT-CM for 120 hours from either 8-10 or 12-14 weeks gestational age. Transverse sections of each artery were stained with H-Cal **(A)**, MyHC **(B)**, α-SMA **(C)** or osteopontin **(D)** and quantified for amount of expression using Adobe Photoshop. Statistical significance was determined by use of an ANOVA with a Fisher's post-hoc test, n=6 each group.



Figure 1






Figure 2












Figure 3



**Figure 4**  
**A**



**B**



**C**

